Pfizer is tapping Blackstone for up to $1.5 billion to fund its weight-loss drug
Blackstone would be eligible for milestone payments tied to U.S. approval of monthly berobenatide, while Pfizer keeps full control
We haven't written up this one. Quartz has the full story — the link below goes straight to it.